Celltrion announced that it has confirmed that Rekironaju, a COVID-19 antibody treatment, is more effective than conventional antibody treatments.
Celltrion R&D Director Kwon Ki-seong attended a discussion meeting jointly held by Lee Gwang-jae, Hwang-hee, and Shin Hyun-young on the 12th and said, "Recyronaju has achieved equal or better results compared to the antibody treatments of Lily and Linezeron."
Lily and Linezeron's antibody treatments are approved for emergency use by the U.S. Food and Drug Administration (FDA).
Celltrion said it has applied for conditional approval from the Korean Food and Drug Administration for the state of Rekirona, and has also begun procedures to obtain emergency use approval in the United States and Europe.
Celltrion plans to release data on the results of Phase 2 clinical trials of Rekkirona at an academic conference hosted by the Korean Pharmacy Society tomorrow afternoon.
(Photo = Yonhap News)